MTP - Midatech Pharma plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+0.0156 (+2.74%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.5700
Bid0.0000 x 3100
Ask0.0000 x 2900
Day's Range0.5680 - 0.6100
52 Week Range0.5600 - 10.9000
Avg. Volume247,634
Market Cap17M
Beta (3Y Monthly)0.71
PE Ratio (TTM)N/A
EPS (TTM)-0.8480
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A

    Midatech Pharma announces confirmation of a €2.6 million EU Grant for further clinical development of MTX110 for the treatment of Diffuse Intrinsic Pontine Glioma, a rare and fatal form of childhood brain cancer

    LONDON, UK / ACCESSWIRE / December 5, 2019 / Midatech Pharma PLC ("Midatech" or the "Company") (AIM:MTPH.L; Nasdaq:MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that it has received confirmation of a €2.6 million EU grant to be used to conduct a ground-breaking clinical study, GlioKIDS, designed to demonstrate the efficacy of MTX110 as a treatment for Diffuse Intrinsic Pontine Glioma ("DIPG"), a rare and fatal form of childhood brain cancer with an average life expectancy of 7 to 9 months. The grant is under the EU EIC Accelerator SME Instrument and is part of the European Innovation Council ("EIC") that supports top class innovators and small companies with funding opportunities to establish market-creating innovations that shape new markets and generate jobs, growth and higher standards of living.

  • Easy Come, Easy Go: How Midatech Pharma (LON:MTPH) Shareholders Torched 97% Of Their Cash
    Simply Wall St.

    Easy Come, Easy Go: How Midatech Pharma (LON:MTPH) Shareholders Torched 97% Of Their Cash

    It's not possible to invest over long periods without making some bad investments. But really bad investments should...


    Midatech Pharma PLC Announces Closing of US$3.0m Registered Direct Offering

    ABINGDON, OXFORDSHIRE / ACCESSWIRE / October 28, 2019 / Midatech Pharma PLC (MTPH.L)(MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, today announced the closing of its previously announced registered direct offering of 3,000,000 of its American Depositary Shares ("ADSs") (each ADS representing 20 of the Company's ordinary shares (the "New Ordinary Shares")) at a purchase price of US$1.00 per ADS (equivalent to 3.9 pence per New Ordinary Share. Additionally, in a concurrent private placement, the Company issued to the Investor unregistered warrants to purchase up to 3,000,000 ADSs ("Warrant ADSs").

  • Midatech Pharma News: MTP Stock Rockets on Diabetes Vaccine Results

    Midatech Pharma News: MTP Stock Rockets on Diabetes Vaccine Results

    Midatech Pharma (NASDAQ:MTP) is on a sweet spot this Friday as the business lifted the veil on its most recent clinical trial, yielding results that were commendable.Source: Shutterstock The United Kingdom-based biopharmaceutical organization said it brought in "positive" results after the first in-human study of its diabetes vaccine. The substance in questions is its MTX102 immuno-tolerising candidate that may have the potential of helping the lives of those who suffer from Type 1 diabetes.Midatech's early success in this matter propelled the brand's trading volume forward as 2.9 million shares exchanged hands, which is many times higher than its full-day average of about 88,000 shares. The company conducted the study by bringing forth five Type 1 diabetes patients in the phase 1 study-this study was designed to determine the safety of MTX102.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"MTX102 was well tolerated, with asymptomatic local injection site reactions being the only drug-related finding, and no serious adverse events were reported," the company wrote.MTP stock is up about 30.8% during regular trading hours today following this news, lifting the share price to $1.70 per share after starting the day with a price of $1.30 per share. Midatech now has a market cap of roughly $32.46 million.However, the MTP per-share price is still far from its 2019 peak of $7.90 that it experienced back in February 27. More From InvestorPlace * 10 Tech Stocks That Are Still Worth Your Time (And Money) * 7 Stocks Top Investors Are Buying Now * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 10 Stocks to Sell for an Economic Slowdown The post Midatech Pharma News: MTP Stock Rockets on Diabetes Vaccine Results appeared first on InvestorPlace.

  • Benzinga

    Midatech Pharma Rallies On Positive MTX102 Results

    Midatech Pharma PLC-ADR (NASDAQ: MTP ) shares were trading higher Friday after the company announced positive results from a first-in-human study of its MTX102 immuno-tolerizing vaccine product candidate ...

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For July 19, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Midatech Pharma PLC (NASDAQ: MTP ) shares ...

  • Zacks Small Cap Research

    MTP: Strategic Refocusing to Pure-Play R&D Company; Pivotal Study of MTD201 to Commence 2H19…

    The company generated total gross revenue of £1.94 million, which included both collaboration income and grant revenue. The increase was primarily due to loan redemption penalties and other costs associated with repaying the loan agreement with MidCap. In January 2019, Midatech announced a strategic licensing deal with Chinese Medical Systems (CMS) that included an equity investment.


    Four Healthcare Stocks Getting A Boost On Wednesday

    While industries like tech and auto develop innovative technologies for consumers, by and large, people can survive without their devices and their cars, but our health supersedes all else. The unrivaled importance of the healthcare sector comes with the expectation that companies working in the space are prepared to meet the growing demands of patients suffering from a multitude of diseases. If healthcare companies continue to provide the best quality care for their patients, this may, in turn, spark investor excitement.

  • Reuters

    BRIEF-China Medical System Holdings Unit Signs Agreement With Midatech Pharma PLC


  • Simply Wall St.

    Here’s What Münchener Tierpark Hellabrunn AG’s (MUN:MTP) P/E Is Telling Us

    The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll look at Münchener Tierpark Hellabrunn AG's (MUN:MTP) P/E ratio and reflect Read More...